Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika
OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular...
Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial
Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a...
EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval
EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...
Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...
FDA Raises Concerns Over Research Conditions at Roche’s Genentech Trial Site
The US Food and Drug Administration (FDA) has voiced concerns regarding the research conditions at...
Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules
Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...
China’s CDE Releases Draft Guidelines for Decentralized Trials in Rare Disease Drug Development
China’s Center for Drug Evaluation (CDE) has released draft “Technical Guidelines for the Application of...
AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market
AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug...
Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia
Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Phase Ib/II Study of Dalpiciclib and HRS-8080
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it received approval from...
Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...
Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China
China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the...
Bayer Invests USD 130 Million in Parenteral Drugs Manufacturing Site in Germany
Bayer (ETR: BAYN) has inaugurated a new state-of-the-art parenteral drugs manufacturing site at its German...
Novo Nordisk Invests DKK 16 Billion to Expand French Production Facility
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has initiated an expansion of its production facility...
Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development
China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop...
European Commission Proposes Overhaul of Pharmaceutical Legislation
The European Commission (EC) is advancing an update to Europe’s 20-year-old pharmaceutical legislation, with the...
Pyrotech Biotechnology’s PTT-936 Gets US FDA Clinical Trial Approval
Pyrotech (Beijing) Biotechnology Co., Ltd, a China-based biotech firm, has announced that it has received...
Boehringer Ingelheim and Eli Lilly’s Jardiance Receives NMPA Approval for CKD Treatment
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance...
Zhejiang Huanqing Medical Technology Secures Series A Financing for Heart Failure Innovations
Zhejiang Huanqing Medical Technology Co., Ltd, a Chinese specialist in heart failure solutions, has reportedly...